Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Bullboard Posts
Post by georgesoreloseon Jun 07, 2017 8:18am
328 Views
Post# 26333983

Josh should really USE the Cormark 3 CENT target as evidense

Josh should really USE the Cormark 3 CENT target as evidenseI'm surprised the "Beech Boy" has NOT once pointed to the 4 CENT, and now reduced to 3 CENT target of Cormark.  Cormark was Spectral's "financing partner" in early 2016.  They placed about 11M EDT shares at 70 cents, mostly in the USA.  

This financing was done while they still had EDT listed as "UNDER REVIEW".  Oddly enough we remained "under review" until May 30 2016, just one day before the EDT AGM.  A new paper was produced and the tone was mostly NEGATIVE, and included a REDUCTION in the target from $1.70 to $1.50.

The analyst, David Novak is a real pro and one of Bay Street's TOP analysts.  He clearly has an EXCELLENT understanding of EDT, so why is Josher not using the 3 CENT target now set by Cormark as his only real example of JUST HOW BAD this is?

I like to help people, so Josher I will now join your crusade and point to all the info I know about the company and Cormark.

I think it will better explain just what is going on

Best regards,
Jorge
Bullboard Posts